Clinical trials: Hepatobiliary Disorders
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Determination of sarcopenia frequency among patients with metabolic dysfunction-associated steatotic liver disease 2- Exploring the association of sarcopenia with disease state (steatosis grade and fibrosis) among patients with…
- Trial name
- NCT07598916
- Volunteers
- 120 people
- Sponsor
- Assiut University
Obesity, Gallstones
Obeticholic Acid in Bariatric and Gallstone Disease
By binding to the nuclear receptor FXR, bile acids not only regulate their own turn-over but presumably also pivotal steps in cholesterol, triglyceride and glucose metabolism as shown in laboratory animals.
- Trial name
- OCABSGS (NCT01625026)
- Testing
- Obeticholic acid
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Sahlgrenska University Hospital
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
Cystic Fibrosis, Cystic Fibrosis Liver Disease
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication
- Trial name
- RECOVER (NCT04602468)
- Testing
- Elexacaftor/Tezacaftor/Ivacaftor
- Where
- 7 sites in Ireland, United Kingdom
- Volunteers
- 206 people
- Sponsor
- Royal College of Surgeons, Ireland
Non-Alcoholic Fatty Liver Disease
Investigation of Synbiotic Treatment in NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver condition in which fat builds up in the liver not caused by alcohol. The liver is an organ that is not designed to build up fat.
- Trial name
- INSYTE (NCT01680640)
- Testing
- Synbiotic, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Fatty Liver
The Effect of a Probiotic on Hepatic Steatosis
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States.
- Trial name
- NCT00099723
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VSL Pharmaceuticals
Nonalcoholic Fatty Liver Disease
Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
Abstract Background: Insulin resistance has an important role in the development of nonalcoholic fatty liver disease (NAFLD) and is involved in both pathological processes: hepatic steatosis and atherosclerosis.
- Trial name
- NCT01084486
- Testing
- Metformin
- Where
- Israel
- Sponsor
- Wolfson Medical Center
HIV Infections, Kidney Disease
Kidney and Liver Transplantation in People With HIV
With improved anti-HIV drug therapy, HIV infected patients are now living longer. These patients are at risk for liver and kidney failure and may need organ transplants.
- Conditions
- HIV Infections, Kidney Disease, Liver Disease
- Trial name
- NCT00074386
- Where
- 21 sites in United States
- Volunteers
- 275 people
- Sponsor
- University of California, San Francisco
Alcohol-related Liver Disease
Contingency Management to Incentivise Treatment Adherence in Alcohol-related Liver Disease
A sample of 30 alcohol-related liver disease patients will be recruited through consecutive sampling, facilitated through the Alcohol Care Team, which will identify potential participants to the study that have been referred to…
- Trial name
- NCT06183710
- Testing
- Contingency management
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College Hospital NHS Trust
Chronic Liver Disease
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation
The objectives of this study are: To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT…
- Trial name
- NCT02084160
- Where
- 4 sites in United States, Israel
- Volunteers
- 579 people
- Sponsor
- Meridian Bioscience, Inc.
Non Alcoholic Fatty Liver, Obesity
Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
Effect of oral selected Probiotics (PRO) and/or Berberine (BBR) supplementation on hepatic steatosis markers, cardiometabolic profile, and gut microbiota profile in the non-alcoholic fatty liver (NAFL) - a randomized double-blind…
- Trial name
- NCT05523024
- Testing
- Probiotic, Berberine, Probiotc and Berberine
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Poznan University of Medical Sciences
Hepatitis C
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.
- Trial name
- ECLIPSE 1 (NCT01025596)
- Testing
- Interleukin-7
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Cytheris SA
MAFLD
Dihydroartemisinin for MAFLD
Brief Summary Purpose: This is a proof-of-concept clinical trial to evaluate whether Dihydroartemisinin (DHA), a medication commonly used to treat malaria, can effectively reduce liver fat in adults with Metabolic Associated…
- Trial name
- NCT07679542
- Testing
- Dihydroartemisinin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic…
- Trial name
- RESOLVE-IT (NCT02704403)
- Testing
- Elafibranor
- Where
- 326 sites in United States, Argentina and 23 more
- Volunteers
- 2,157 people
- Sponsor
- Genfit
Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.
- Trial name
- NCT06218342
- Testing
- Henagliflozin, Background medication
- Volunteers
- 156 people
- Sponsor
- Sir Run Run Shaw Hospital
Liver Disease, Cirrhosis of the Liver
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease
This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease…
- Conditions
- Liver Disease, Cirrhosis of the Liver, Acute-On-Chronic Liver Failure, Liver Failure
- Trial name
- NCT04116242
- Testing
- blood sampling for research purpose, clinical data collection, Health-related Questionnaires
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
End Stage Liver Disease, Acute Kidney Injury
Effect of Preoperative Beta Blocker Use Postoperative Renal Function in the Patients Undergoing Liver Transplantation
This is prospective cohort study of patients classified by the premedication history of beta-blocker. The investigators aim to evaluate the hemodynamic effect of beta blocker through Swan-Ganz catheter monitoring and arterial…
- Trial name
- NCT03633812
- Testing
- Observational study, Beta blocker medication history
- Where
- 2 sites in South Korea
- Volunteers
- 477 people
- Sponsor
- Asan Medical Center
Acute Cholecystitis
Functional MRC With Eovist for Acute Cholecystitis
Functional magnetic resonance cholangiography (fMRC) with gadoxetate disodium (Eovist) is an accurate method of diagnosing acute cholecystitis.
- Trial name
- MRC (NCT02100358)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Davis
Hepatocellular Carcinoma, Biliary Tract Cancer
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Although immune checkpoint inhibitors including nivolumab and pembrolizumab are now available for the management of hepatobiliary cancers in Korea, there is a lack of data for the efficacy and safety of these agents in the…
- Trial name
- NCT03695952
- Testing
- Nivolumab or pembrolizumab
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.